0.33 USD
▲+0.00+4.90%
盘后 0.31 +0.32%
2026-08-03
市值
$6.96M
市盈率
—
EPS
-0.30
股息率
—
52 周区间
0.27 – 2.11
成交量
477.76K
Beta
—
目标价
7.00
52W 低 0.2752W 高 2.11
价格走势
公司简介
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company’s pro...